[en] Introduction Nationwide studies comparing patients with
hepatitis B and C virus (HBV and HCV) infections are
mandatory for assessing changes in epidemiology.
Aim The aim of this study was to compare epidemiological
data and initial management of newly diagnosed patients
with persistent HBV (HBsAg positive) or HCV (detectable
HCV RNA) infection in Belgium.
Patients and methods Data were extracted from two
Belgian observational databases.
Results A total of 655 patients (387 HBV and 268 HCV)
were included. Compared with HCV patients, HBV patients
were younger, more frequently men, more often of Asian or
African origin (43 vs. 10%, P < 0.0001), and less frequently
contaminated by transfusion or intravenous drug use
(9 and 6% vs. 34 and 44%, P< 0.0001). Viral replication was
assessed in 89% of HBV patients. Compared with HCV
patients, HBV patients more frequently had normal alanine
aminotransferase (ALT) levels (65 vs. 29%, P < 0.0001), less
frequently underwent liver biopsy (29 vs. 67%, P < 0.0001),
and were less often considered for antiviral therapy
(25 vs. 54%, P < 0.0001). When taking only HBV patients
with detectable viral replication into consideration, results
remained unchanged. During the multivariate analysis,
ALT was a major factor for performing liver biopsy or
considering antiviral therapy in both groups.
Conclusion HBV and HCV screening policies should be
targeted toward immigrants and intravenous drug users,
respectively. Guidelines recommending systematic search
for viral replication should be reinforced in HBV patients.
HBV patients less frequently underwent liver biopsy and
were less often considered for antiviral therapy compared
with HCV patients. Despite the lack of sensitivity and
specificity, ALT remains a pivotal decision-making tool for
liver biopsy and antiviral therapy in both infections.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
De Vroey, B
Moreno, C
Laleman, W
Van Gossum, M
Colle, I
de Galocsy, C
Langlet, P
Robaeys, G
Orlent, H
Michielsen, P
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmouliere A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006; 38:135-151. (Pubitemid 41619443)
Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis - role of cytokines and different cell types. Z Gastroenterol 2007; 45:77-86. (Pubitemid 46205999)
Dienes HP, Drebber U. Pathology of immune-mediated liver injury. Dig Dis 2010; 28:57-62.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745. (Pubitemid 27527771)
Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-136. (Pubitemid 30430422)
Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48:148-162. (Pubitemid 350191999)
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28:112-125. (Pubitemid 44289094)
Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008; 13:1-8.
Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49:S28-S34.
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-1339. (Pubitemid 41819540)
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008; 49:175-183.
Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, et al. Impact of national treatment practices on future HCV burden in six European countries: a model-based analysis. Gastroenterology Gastroenterology 2012; 143:974-985.
Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997; 13:275-280. (Pubitemid 27306072)
Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol 2007; 22:195-202. (Pubitemid 46481328)
Deltenre P, Laleman W, Van Gossum M, Lenaerts A, Colle I, Michielsen P, et al. HBV infection in Belgium: results of the BASL observatory of 1,456 HBsAg carriers. Acta Gastroenterol Belg 2012; 75:35-41.
De Maeght S, Henrion J, Bourgeois N, de Galocsy C, Langlet P, Michielsen P, et al. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol Belg 2008; 71:4-8. (Pubitemid 351613478)
French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15-20.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009; 49:S22-S27.
Gerard C, Delwaide J, Vaira D, Bastens B, Servais B,Wain E, et al. Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. J Med Virol 2005; 76:503-510. (Pubitemid 40943260)
Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-3277. (Pubitemid 27505758)
Cadranel JF, Lahmek P, Causse X, Bellaiche G, Bettan L, Fontanges T, et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis - results of a nationwide survey. Aliment Pharmacol Ther 2007; 26:565-576. (Pubitemid 47174285)
Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006; 45:355-360. (Pubitemid 44160628)
Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31 (Suppl 1):80-83. (Pubitemid 30002696)
Wong WW, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011; 31:1179-1190.
Lo Re V III. Economic analysis of hepatitis B screening and treatment. Clin Infect Dis 2011; 52:1307-1309.
Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011; 52:1294-1306.
Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011; 31:755-761.
Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-1699.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
Deltenre P. Virological tools for optimal management of chronic hepatitis C. Acta Gastroenterol Belg 2009; 72:421-424.
Hollingsworth RC, Sillekens P, van Deursen P, Neal KR, Irving WL. Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. J Hepatol 1996; 25:301-306. (Pubitemid 26323467)
Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, Donato MF, et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 1996; 3:183-190. (Pubitemid 126733933)
Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134:1376-1384. (Pubitemid 351615375)
Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328:983.
Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27:1213-1219. (Pubitemid 28227846)
